New Pediatric Labeling Information Database - Detail

Please note: JavaScript must be enabled for this application to work properly.
Check your settings if you are unsure
if your JavaScript is enabled.

Pediatric Labeling Date:

04/07/2008

Trade Name:

Orencia

Generic Name or Proper Name (*):

abatacept

Indications Studied:

Moderate to severe polyarticular juvenile idiopathic arthritis

Label Changes Summary:

* Indicated for reducing signs and symptoms in pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) ages 6 years and older. * The safety and effectiveness in pediatric patients < 6 years of age and in pediatric patients for uses other than JIA have not been established * Abatacept was studied in 190 patients 6 - 17 years with polyarticular JIA. * AEs were generally similar to those seen in adults. Overall frequency of adverse events in the 4-month, lead-in, open-label period of the study was 70%; infections occurred at a frequency of 36%. A total of 6 serious adverse events were reported during the initial 4 months of treatment with abatacept. * Information on dosing, PK, immunogenicity, immunization needs, AEs, and clinical study * New indication